Managing Transition in Patients Treated with Growth Hormone
Growth hormone (GH) promotes growth in children, but is also essential for bone strength, body composition, metabolic factors, such as lipid profile, and maintenance of quality of life. The Merck KGaA (Germany) funded “360° GH in Europe” meeting, held in Lisbon, Portugal, in June 2016, comprised thr...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2017-12-01
|
Series: | Frontiers in Endocrinology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/article/10.3389/fendo.2017.00346/full |
id |
doaj-4c3dcf020dc2420992eeb42234324901 |
---|---|
record_format |
Article |
spelling |
doaj-4c3dcf020dc2420992eeb422343249012020-11-24T20:44:21ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922017-12-01810.3389/fendo.2017.00346296728Managing Transition in Patients Treated with Growth HormoneBerthold P. Hauffa0Philippe Touraine1Tanya Urquhart-Kelly2Ekaterina Koledova3Department of Pediatric Endocrinology, University of Duisburg-Essen, Essen, GermanyDepartment of Endocrinology and Reproductive Medicine, Centre des Maladies Endocriniennes Rares de la Croissance et du Développement, Paris, FranceDepartment of Nursing and Midwifery, Sheffield Hallam University, Sheffield, United KingdomGlobal Medical Affairs, Merck KGaA, Darmstadt, GermanyGrowth hormone (GH) promotes growth in children, but is also essential for bone strength, body composition, metabolic factors, such as lipid profile, and maintenance of quality of life. The Merck KGaA (Germany) funded “360° GH in Europe” meeting, held in Lisbon, Portugal, in June 2016, comprised three sessions entitled “Short Stature Diagnosis and Referral,” “Optimizing Patient Management and Adherence,” and “Managing Transition.” The scientific program covered all stages of pediatric GH treatment, and reported here are the outcomes of the third session of the meeting, which considered transition from pediatric GH treatment to teenage and young adult GH therapy. A large number of patients with chronic diseases, including GH deficiency, drop out of therapy during the transition period. Multiple factors are associated with this, such as lack of understanding of the disease process, insufficient knowledge of treatment options, the patient becoming more independent, and requirement for interaction with a new set of health-care workers. Education regarding disease management and treatment options should be provided from an early age and right through the transition period. However, endocrine specialists will view the transition period differently, depending on whether they are pediatric endocrinologists who mainly deal with congenital diseases, in which auxology is important, or adult endocrinologists who are more concerned with body composition and metabolic factors. View points of both a pediatric and an adult endocrine specialist are presented, together with a case study outlining practical aspects of transition. It was noted in the meeting discussion that having one person to guide a patient through transition from an early age is important, but may be constrained by various factors such as finances, and options will differ by country.http://journal.frontiersin.org/article/10.3389/fendo.2017.00346/fullgrowth hormone deficiencypediatricadolescenttransitionpersonalized medicineendocrinology |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Berthold P. Hauffa Philippe Touraine Tanya Urquhart-Kelly Ekaterina Koledova |
spellingShingle |
Berthold P. Hauffa Philippe Touraine Tanya Urquhart-Kelly Ekaterina Koledova Managing Transition in Patients Treated with Growth Hormone Frontiers in Endocrinology growth hormone deficiency pediatric adolescent transition personalized medicine endocrinology |
author_facet |
Berthold P. Hauffa Philippe Touraine Tanya Urquhart-Kelly Ekaterina Koledova |
author_sort |
Berthold P. Hauffa |
title |
Managing Transition in Patients Treated with Growth Hormone |
title_short |
Managing Transition in Patients Treated with Growth Hormone |
title_full |
Managing Transition in Patients Treated with Growth Hormone |
title_fullStr |
Managing Transition in Patients Treated with Growth Hormone |
title_full_unstemmed |
Managing Transition in Patients Treated with Growth Hormone |
title_sort |
managing transition in patients treated with growth hormone |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Endocrinology |
issn |
1664-2392 |
publishDate |
2017-12-01 |
description |
Growth hormone (GH) promotes growth in children, but is also essential for bone strength, body composition, metabolic factors, such as lipid profile, and maintenance of quality of life. The Merck KGaA (Germany) funded “360° GH in Europe” meeting, held in Lisbon, Portugal, in June 2016, comprised three sessions entitled “Short Stature Diagnosis and Referral,” “Optimizing Patient Management and Adherence,” and “Managing Transition.” The scientific program covered all stages of pediatric GH treatment, and reported here are the outcomes of the third session of the meeting, which considered transition from pediatric GH treatment to teenage and young adult GH therapy. A large number of patients with chronic diseases, including GH deficiency, drop out of therapy during the transition period. Multiple factors are associated with this, such as lack of understanding of the disease process, insufficient knowledge of treatment options, the patient becoming more independent, and requirement for interaction with a new set of health-care workers. Education regarding disease management and treatment options should be provided from an early age and right through the transition period. However, endocrine specialists will view the transition period differently, depending on whether they are pediatric endocrinologists who mainly deal with congenital diseases, in which auxology is important, or adult endocrinologists who are more concerned with body composition and metabolic factors. View points of both a pediatric and an adult endocrine specialist are presented, together with a case study outlining practical aspects of transition. It was noted in the meeting discussion that having one person to guide a patient through transition from an early age is important, but may be constrained by various factors such as finances, and options will differ by country. |
topic |
growth hormone deficiency pediatric adolescent transition personalized medicine endocrinology |
url |
http://journal.frontiersin.org/article/10.3389/fendo.2017.00346/full |
work_keys_str_mv |
AT bertholdphauffa managingtransitioninpatientstreatedwithgrowthhormone AT philippetouraine managingtransitioninpatientstreatedwithgrowthhormone AT tanyaurquhartkelly managingtransitioninpatientstreatedwithgrowthhormone AT ekaterinakoledova managingtransitioninpatientstreatedwithgrowthhormone |
_version_ |
1716817582725529600 |